Navigation Links
CryoCath Appoints Vice President, Europe
Date:7/2/2008

http://www.cryocath.com Toronto Stock Exchange Symbol: CYT

MONTREAL, July 2 /PRNewswire-FirstCall/ - CryoCath Technologies Inc. (TSX: CYT), the global leader in cryotherapy products to treat cardiac arrhythmias, today announced the appointment of Frank Vandeputte as Vice President, Europe. Based in CryoCath's new European headquarters in Leiden, The Netherlands, Mr. Vandeputte will be responsible for leading the European business operation. This includes the development and implementation of strategic and operational business plans, with the objective of driving ongoing rapid sales growth of the Company's innovative products in the European market.

Mr. Vandeputte joins CryoCath with more than 20 years of experience in the medical device industry. Most recently, he served as Area Vice President Benelux and Nordic for the Sorin Group, based in Brussels. Prior to that he was Vice President International Marketing with the Sorin Group. Prior to Sorin, he held senior management positions with leading medical device companies, including Baxter International Inc, Becton Dickinson and Guidant Corporation. With Guidant, he has been providing leadership to their European Cardiac Resynchronisation Therapy, Endovascular and Cardiac Surgery business, and served as Country Manager for Germany as well.

"With his proven leadership and medical device industry successes, Frank will be an asset to our European commercial operations. He, and his successful European leadership team, will spearhead the ongoing rapid growth of Arctic Front in Europe," said Jan Keltjens, CryoCath President and CEO. "Additionally, we have now opened our European headquarters in Leiden, the Netherlands. This will allow us to better serve the needs of our expanding customer base in Europe. By establishing a strong European presence and enhancing our management team, we are continuing to execute on our strategy of becoming a leader in atrial fibrillation therapy."

About CryoCath

--------------

CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes "forward looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.


'/>"/>
SOURCE CryoCath Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCath files patent infringement lawsuit
2. CryoCath to present at CIBC Healthcare Conference
3. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
4. CryoCath announces 2007 fourth quarter and fiscal year end financial results
5. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
6. CryoCath to Hold First Quarter 2008 Conference Call and Webcast
7. CryoCath Provides Update on Patent Infringement Lawsuit
8. CryoCath Announces Fiscal 2008 First Quarter Results
9. CryoCath Technologies notice of annual meeting
10. CryoCath Appoints New Chief Financial Officer
11. CryoCath Introduces Arctic Front in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Prater Eye Center becomes the first in the area to offer AngioPlex™ Optical ... signs of retinal disease, such as macular degeneration, diabetic retinopathy, and other vascular ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Many individuals ... of protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved ... it once more, but without the high-carb repercussions. IsoPasta has 30 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, ... gift of a VeinViewer® Vision vein finder for the nursing school ... an IV and draw blood, combining technology with traditional technique. , “VeinViewer is ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... According ... hernia surgeries are beginning to account for a significant portion of hernia repairs throughout ... Towfigh of the Beverly Hills Hernia Center notes that this trend has not only ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted over 250 members of South Florida’s philanthropic community at its 10th ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)...  Sequent Medical, Inc. announced today that it has ... safety and effectiveness of the WEB™ Aneurysm Embolization System ... Prof Laurent Spelle , MD, Head of Neuroradiology ... and Principal Investigator of the CLARYS study, ... and Germany.  Although patients with ruptured aneurysms have ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology: